JP2011132229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011132229A5 JP2011132229A5 JP2010270287A JP2010270287A JP2011132229A5 JP 2011132229 A5 JP2011132229 A5 JP 2011132229A5 JP 2010270287 A JP2010270287 A JP 2010270287A JP 2010270287 A JP2010270287 A JP 2010270287A JP 2011132229 A5 JP2011132229 A5 JP 2011132229A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- spongosine
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000002193 Pain Diseases 0.000 claims 17
- AJACDNCVEGIBNA-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-amino-2-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(OC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O AJACDNCVEGIBNA-KQYNXXCUSA-N 0.000 claims 13
- AJACDNCVEGIBNA-UHFFFAOYSA-N 2-Methoxyadenosine Natural products C12=NC(OC)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O AJACDNCVEGIBNA-UHFFFAOYSA-N 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000004296 neuralgia Diseases 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 3
- 208000004454 Hyperalgesia Diseases 0.000 claims 3
- 208000035154 Hyperesthesia Diseases 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 229940035676 analgesics Drugs 0.000 claims 3
- 239000000730 antalgic agent Substances 0.000 claims 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 3
- 108090000312 Calcium Channels Proteins 0.000 claims 2
- 102000003922 Calcium Channels Human genes 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 206010063094 Cerebral malaria Diseases 0.000 claims 2
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229940121954 Opioid receptor agonist Drugs 0.000 claims 2
- 208000000450 Pelvic Pain Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 108010052164 Sodium Channels Proteins 0.000 claims 2
- 102000018674 Sodium Channels Human genes 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000003402 opiate agonist Substances 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000004031 partial agonist Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010000087 Abdominal pain upper Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 206010050219 Lumbar radiculopathy Diseases 0.000 claims 1
- 206010027202 Meningitis bacterial Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims 1
- 206010028836 Neck pain Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010061339 Perineal pain Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039203 Road traffic accident Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000026816 acute arthritis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 1
- 229960003942 amphotericin b Drugs 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000009904 bacterial meningitis Diseases 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 230000036471 bradycardia Effects 0.000 claims 1
- 208000006218 bradycardia Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000011379 keloid formation Diseases 0.000 claims 1
- 201000003866 lung sarcoma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000009772 tissue formation Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0228723.3 | 2002-12-09 | ||
| GBGB0228723.3A GB0228723D0 (en) | 2002-12-09 | 2002-12-09 | Treatment of pain |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004558826A Division JP4836454B2 (ja) | 2002-12-09 | 2003-12-09 | 疼痛、特に痛覚過敏治療のための、スポンゴシン（２−メトキシアデノシン）の使用。 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011132229A JP2011132229A (ja) | 2011-07-07 |
| JP2011132229A5 true JP2011132229A5 (enExample) | 2012-06-28 |
Family
ID=9949371
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004558826A Expired - Fee Related JP4836454B2 (ja) | 2002-12-09 | 2003-12-09 | 疼痛、特に痛覚過敏治療のための、スポンゴシン（２−メトキシアデノシン）の使用。 |
| JP2010270287A Withdrawn JP2011132229A (ja) | 2002-12-09 | 2010-12-03 | 疼痛、特に痛覚過敏治療のための、スポンゴシン（２−メトキシアデノシン）の使用。 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004558826A Expired - Fee Related JP4836454B2 (ja) | 2002-12-09 | 2003-12-09 | 疼痛、特に痛覚過敏治療のための、スポンゴシン（２−メトキシアデノシン）の使用。 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8252766B2 (enExample) |
| EP (1) | EP1581235B1 (enExample) |
| JP (2) | JP4836454B2 (enExample) |
| KR (1) | KR101122495B1 (enExample) |
| CN (2) | CN101264097B (enExample) |
| AT (1) | ATE430572T1 (enExample) |
| AU (1) | AU2003288451B2 (enExample) |
| CA (1) | CA2507918A1 (enExample) |
| CY (1) | CY1109229T1 (enExample) |
| DE (1) | DE60327557D1 (enExample) |
| DK (1) | DK1581235T3 (enExample) |
| ES (1) | ES2326532T3 (enExample) |
| GB (2) | GB0228723D0 (enExample) |
| NO (1) | NO20053042L (enExample) |
| NZ (1) | NZ540353A (enExample) |
| PT (1) | PT1581235E (enExample) |
| SI (1) | SI1581235T1 (enExample) |
| WO (1) | WO2004052377A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| GB0305149D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| SG144146A1 (en) * | 2004-03-05 | 2008-07-29 | Cambridge Biotechnology Ltd | Adenosine receptor agonists |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| AU2007263727A1 (en) | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | 2-0'-methyladen0sine derivatives and their use as agonists or antagonists of an adenosine receptor |
| AU2007263726A1 (en) | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
| NZ573308A (en) * | 2006-06-27 | 2012-02-24 | Biovitrum Ab Publ | Adenosine derivatives for the treatment of pain |
| CN101938904A (zh) * | 2008-01-09 | 2011-01-05 | PGx健康有限责任公司 | 用a2ar激动剂鞘内治疗神经性疼痛 |
| US8221791B1 (en) | 2008-12-10 | 2012-07-17 | University Of Central Florida Research Foundation, Inc. | Silica-based antibacterial and antifungal nanoformulation |
| SG177557A1 (en) * | 2009-07-09 | 2012-02-28 | Cbt Dev Ltd | Combined preparation for use as a medicament |
| US20130123208A1 (en) * | 2010-05-12 | 2013-05-16 | The Regents of the University of Colorado, a body corporation | Method of treating multiple sclerosis with adenosine receptor agonists |
| EP2631345B1 (en) * | 2012-02-27 | 2019-09-04 | Electrolux Home Products Corporation N.V. | Washing tub unit and washing machine |
| US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| CN108697701B (zh) * | 2016-02-04 | 2021-10-26 | 约翰霍普金斯大学 | 平衡型核苷转运蛋白1的抑制剂Rapadocin及其用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4861498A (enExample) | 1971-12-01 | 1973-08-28 | ||
| BE792155A (fr) | 1971-12-01 | 1973-05-30 | Takeda Chemical Industries Ltd | Nouveaux derives de l'adenosine et leur procede de production |
| DE2359536C2 (de) * | 1972-12-08 | 1984-08-02 | Takeda Chemical Industries, Ltd., Osaka | 2,6-Diaminonebularinderivate |
| JPS5549594B2 (enExample) | 1972-12-08 | 1980-12-12 | ||
| JPS5461194A (en) * | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | Preparation of n22substituted 2*66diaminonebularin |
| JPS5461195A (en) | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | N2-substituted phenyl-2,6-diaminonebularin |
| US4705758A (en) * | 1984-06-19 | 1987-11-10 | Warner-Lambert Company | Adenosine receptor assay and kit |
| US5104859A (en) * | 1985-09-24 | 1992-04-14 | Solimedco Aktiebolag | Continuous administration of adenosine to reduce pulmonary vascular resistance |
| US5231086A (en) * | 1985-09-24 | 1993-07-27 | Item Development Aktiebolag | Continuous administration adenosine to increase myocardial blood flow |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5140015A (en) | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
| US6180616B1 (en) * | 1990-05-10 | 2001-01-30 | Atsuo F. Fukunaga | Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function |
| US5679650A (en) * | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
| US6004945A (en) * | 1990-05-10 | 1999-12-21 | Fukunaga; Atsuo F. | Use of adenosine compounds to relieve pain |
| US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
| AU6516494A (en) | 1993-04-15 | 1994-11-08 | New York University | Adenosine receptor agonists for the promotion of wound healing |
| US5683989A (en) * | 1993-12-17 | 1997-11-04 | Novo Nordisk A/S | Treatment of ischemias by administration of 2,N6 -substituted adenosines |
| SE9401499D0 (sv) | 1994-05-02 | 1994-05-02 | Item Dev Ab | New method of treatment |
| HUT75338A (en) | 1994-05-10 | 1997-05-28 | Sandoz Ag | Adenosine derivatives, their preparation and use, and pharmaceutical preparations containing them |
| US5596094A (en) * | 1994-05-26 | 1997-01-21 | Sandoz Ltd. | Process for preparing 2' -0- alkyl adenosine derivatives |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| IT1275420B (it) | 1995-06-02 | 1997-08-05 | Schering Plough S P A | Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261 |
| EP0983768A1 (en) | 1997-05-23 | 2000-03-08 | Nippon Shinyaku Co., Ltd. | Medicinal composition for prevention or treatment of hepatopathy |
| US6110902A (en) * | 1997-06-23 | 2000-08-29 | Moehler; Hanns | Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine |
| AU8764398A (en) | 1997-07-29 | 1999-02-22 | Medco Research, Inc. | N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| US6440455B1 (en) | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
| GB9723590D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| WO1999034804A1 (en) | 1998-01-08 | 1999-07-15 | The University Of Virginia Patent Foundation | A2a adenosine receptor agonists |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| CA2551169A1 (en) | 2002-12-23 | 2004-07-08 | Global Cardiac Solutions Pty Ltd | Organ preconditioning, arrest, protection, preservation and recovery |
| GB0305153D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
| GB0305150D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
| GB0305149D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| SG144146A1 (en) | 2004-03-05 | 2008-07-29 | Cambridge Biotechnology Ltd | Adenosine receptor agonists |
| US8407664B2 (en) | 2005-12-30 | 2013-03-26 | Sap Ag | Software model business objects |
-
2002
- 2002-12-09 GB GBGB0228723.3A patent/GB0228723D0/en not_active Ceased
-
2003
- 2003-12-09 AU AU2003288451A patent/AU2003288451B2/en not_active Ceased
- 2003-12-09 AT AT03780370T patent/ATE430572T1/de active
- 2003-12-09 KR KR1020057010441A patent/KR101122495B1/ko not_active Expired - Fee Related
- 2003-12-09 SI SI200331633T patent/SI1581235T1/sl unknown
- 2003-12-09 EP EP03780370A patent/EP1581235B1/en not_active Expired - Lifetime
- 2003-12-09 WO PCT/GB2003/005379 patent/WO2004052377A1/en not_active Ceased
- 2003-12-09 ES ES03780370T patent/ES2326532T3/es not_active Expired - Lifetime
- 2003-12-09 CN CN2008100922507A patent/CN101264097B/zh not_active Expired - Fee Related
- 2003-12-09 GB GB0328548A patent/GB2396108B/en not_active Expired - Fee Related
- 2003-12-09 CA CA002507918A patent/CA2507918A1/en not_active Abandoned
- 2003-12-09 JP JP2004558826A patent/JP4836454B2/ja not_active Expired - Fee Related
- 2003-12-09 DK DK03780370T patent/DK1581235T3/da active
- 2003-12-09 DE DE60327557T patent/DE60327557D1/de not_active Expired - Lifetime
- 2003-12-09 US US10/537,564 patent/US8252766B2/en not_active Expired - Fee Related
- 2003-12-09 NZ NZ540353A patent/NZ540353A/en not_active IP Right Cessation
- 2003-12-09 CN CNB2003801055073A patent/CN100471503C/zh not_active Expired - Fee Related
- 2003-12-09 PT PT03780370T patent/PT1581235E/pt unknown
-
2005
- 2005-06-21 NO NO20053042A patent/NO20053042L/no not_active Application Discontinuation
-
2009
- 2009-07-14 CY CY20091100733T patent/CY1109229T1/el unknown
-
2010
- 2010-08-20 US US12/859,932 patent/US20110184065A1/en not_active Abandoned
- 2010-12-03 JP JP2010270287A patent/JP2011132229A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011132229A5 (enExample) | ||
| JP2006514638A5 (enExample) | ||
| JP2022095640A (ja) | ナトリウム（２ｒ，５ｓ，１３ａｒ）－７，９－ジオキソ－１０－（（２，４，６－トリフルオロベンジル）カルバモイル）－２，３，４，５，７，９，１３，１３ａ－オクタヒドロ－２，５－メタノピリド［１’，２’：４，５］ピラジノ［２，１－ｂ］［１，３］オキサゼピン－８－オレート | |
| US9624195B2 (en) | Isoquinoline compounds | |
| US20110184065A1 (en) | Use of spongosine for the treatment of pain | |
| JP2006519823A5 (enExample) | ||
| WO2015130966A1 (en) | Antiviral agents | |
| JP2018521993A5 (enExample) | ||
| JP2017501140A5 (enExample) | ||
| US20080261984A1 (en) | Use of S,S-Reboxetine in the Treatment of Pain | |
| JP2015511588A5 (enExample) | ||
| US10933062B2 (en) | Analgesic therapeutic and method, 1-(3-4(((1 R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof | |
| RU2012115450A (ru) | Применение антагонистов опиоидных рецепторов при заболеваниях желудочно-кишечного тракта | |
| Zhang et al. | UTL-5g Lowers Elevated Blood Levels of TNF-α and TGF-β and Increases Survival Rates in Animals Treated with LPS/D-(+)-galactosamine | |
| WO2017093212A1 (en) | Tablet formulations of nimesulide and thiocolchicoside | |
| CN101208095A (zh) | 瑞波西汀在治疗疼痛中的应用 | |
| JPWO2017126648A1 (ja) | Ｎ−［７−［（メチルスルホニル）アミノ］−４−オキソ−６−フェノキシ−４ｈ−１−ベンゾピラン−３−イル］ホルムアミドまたはその塩を含有する医薬組成物 | |
| CA2711885A1 (en) | (e)-n-{3-[1-(8-fluoro-11h-10-oxa-1-aza-dibenzo [a,d] cyclohepten-5ylidene)-propyl]-phenyl}-methanesulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis | |
| CN109364078A (zh) | 纳洛酮在制备镇痛药物中的应用 | |
| RU2013107009A (ru) | Витамин с и не содержащий хрома витамин к, а также композиции, содержащие указанные витамины, для лечения nfkb-опосредованного состояния или заболевания |